 |
Molika Ashford is a GenomeWeb contributing editor and covers personalized medicine and molecular diagnostics. E-mail Molika Ashford. |
HTG to Commercialize PROOF's COPD Risk Stratification Test; Aims for Launch Next Year
December 05, 2012
HTG to Commercialize PROOF's COPD Risk Stratification Test; Aims for Launch Next Year
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Data Supports Oncotype DX for Predicting Recurrence in Node-Positive Cancers, Guiding Radiation Therapy
March 13, 2013 / Pharmacogenomics Reporter - Canada's PROOF Center to Develop Risk Stratification Test to Personalize COPD Treatment
April 25, 2012 / Pharmacogenomics Reporter - HTG, Sanofi Collaborating to Identify B-Cell Response Markers for Cancer Drug
April 11, 2012 / Pharmacogenomics Reporter - GenomeWeb Feature: The Rise of Lung Cancer Genetic Testing
May 8, 2013 / Pharmacogenomics Reporter - Greenville Health System, Roswell Park Adopt Targeted Sequencing in Cancer Treatment
May 8, 2013 / Clinical Sequencing News